Terry Pirovolakis, CEO of Elpida Therapeutics, achieved what many parents in the ultrarare-disease community aspire to: developing a therapy for his son. He sat down with us to discuss the lessons that he learned as he navigated the whole drug-discovery process in less than two years, laying out the foundation for what now is Elpida.
Terry Pirovolakis, CEO of Elpida Therapeutics, achieved what many parents in the ultrarare-disease community aspire to: developing a therapy for his son. He sat down with us to discuss the lessons that he learned as he navigated the whole drug-discovery process in less than two years, laying out the foundation for what now is Elpida.